CentralCharts: Supercharge your portfolio with groundbreaking tools.

AXTI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AXT Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! PR Newswire NEW YORK, May 8, 2024 NEW YORK , May 8, 2024 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AXT Inc ("AXT" or "the Company") (NASDAQ: AXTI) and certain of its officers. Class Definition: This...

TORONTO, ON / ACCESSWIRE / May 8, 2024 / Lahontan Gold Corp (TSXV:LG)(OTCQB:LGCXF) (the " Company " or " Lahontan ") announces that it has granted an aggregate of 9,100,000 options to purchase common shares of the Company exercisable at a price of $0.08 per common share for a period of five (5) years to directors, officers and consultants of the Company. The common shares issuable upon exercise of the options are subject to a four month hold period from the original date of grant. On behalf of...

ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its...

MEXICO CITY, May 08, 2024 (GLOBE NEWSWIRE) -- Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central, and South America, welcomes Frontier Airlines reactivation of the Codeshare agreement between both airlines, facilitating travel between the United States and Mexico. Beginning today, Frontier customers will be able to book travel to Mexico on Volaris...

Renova Has Prioritized Two Primary Regulatory Pathways Where It Is Poised to Launch Pivotal Human Trials for Its Promising Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus CARLSBAD, CA / ACCESSWIRE / May 8, 2024 / Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene therapies on two primary...